# Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

> **NCT05319756** · PHASE4 · COMPLETED · sponsor: **Viatris Specialty LLC** · enrollment: 54 (actual)

## Conditions studied

- Abuse Potential

## Interventions

- **DRUG:** gabapentin 600 mg
- **DRUG:** gabapentin 1200 mg
- **DRUG:** gabapentin 600 mg and oxycodone HCl 20 mg
- **DRUG:** gabapentin 1200 mg and oxycodone HCl 20 mg
- **DRUG:** oxycodone HCl 20 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05319756
- **Lead sponsor:** Viatris Specialty LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-30
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05319756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05319756, "Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05319756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*